Elisabeth Quoix, et al.
Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article
Publication
TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
Par alcyon|2019-07-03T10:03:16+02:00novembre 12th, 2014|Publication, TG4010|Commentaires fermés sur TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
À propos de l'auteur : alcyon
Articles similaires
- Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
- BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
- Transgene communique sur l’essai clinique de combinaison de TG4010 avec la chimiothérapie et nivolumab dans le traitement du cancer du poumon non à petites cellules
Transgene communique sur l’essai clinique de combinaison de TG4010 avec la chimiothérapie et nivolumab dans le traitement du cancer du poumon non à petites cellules